RP23-132J20.17 Inhibitors
RP23-132J20.17 inhibitors encompass a range of chemical compounds that interact with various signaling pathways to reduce the functional activity of the protein. Compounds like Wortmannin and LY294002 target the phosphoinositide 3-kinases (PI3K) pathway, which is crucial for many cellular processes including cell growth and survival, by inhibiting PI3K these inhibitors could potentially prevent the activation of downstream effectors such as AKT, leading to decreased RP23-132J20.17 activity if it is a downstream target. Similarly, the PI3K/AKT pathway inhibitor LY294002 would have the same effect, assuming RP23-132J20.17 is a part of this signaling cascade. Rapamycin, through its inhibition of mTOR, could lead to a reduction in the protein synthesis and cell growth-related roles of RP23-132J20.17 if it is mTOR-regulated. Moreover, specific kinase inhibitors like PD98059 and U0126 disrupt the MAPK/ERK pathway and, depending on RP23-132J20.17's involvement in this route, could result in its decreased activity. Further, SB203580 hampers the p38 MAP kinase, potentially attenuating RP23-132J20.17 functions linked to stress response signaling, while SP600125's inhibition of JNK could lead to similar outcomes if JNK pathways regulate RP23-132J20.17.
Additionally, inhibitors like ZM-447439, Dasatinib, Bortezomib, Thapsigargin, and Staurosporine offer a wider spectrum of mechanisms for potentially diminishing RP23-132J20.17 activity. ZM-447439's action on Aurora kinases, if related to RP23-132J20.17's function in cell cycle control, would translate to lower protein activity. Dasatinib, a broad-spectrum tyrosine kinase inhibitor, could suppress RP23-132J20.17 if it relies on Src family kinase signaling. Bortezomib's proteasome inhibition may reduce RP23-132J20.17's function assuming it is regulated through proteasomal degradation. Thapsigargin alters calcium homeostasis and could disrupt RP23-132J20.17's activity if it is calcium-sensitive. Lastly, Staurosporine, given its widespread kinase inhibition, could decrease RP23-132J20.17's activity if the protein is influenced by certain kinase pathways, highlighting the diverse strategies through which these inhibitors could conceivably modulate RP23-132J20.17 function.
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3Ks). By inhibiting PI3K, it prevents the phosphorylation and activation of downstream targets such as AKT. If RP23-132J20.17 is a downstream target of AKT, wortmannin would lead to the decreased functional activity of RP23-132J20.17 through this pathway. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin) by binding to its immunophilin receptor FKBP12. The mTOR pathway is critical for protein synthesis and cell growth. If RP23-132J20.17 functions are modulated by mTOR signaling, rapamycin would decrease its activity through inhibiting mTOR. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a specific inhibitor of phosphoinositide 3-kinases (PI3K). It inhibits the PI3K/AKT signaling pathway, potentially reducing the activity of RP23-132J20.17 if it is a downstream effector in this pathway. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of the MAPK/ERK pathway. It acts by inhibiting MEK, which is upstream of ERK in the pathway. If RP23-132J20.17 is regulated by the ERK signaling, PD98059 would indirectly inhibit its activity by blocking this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a selective inhibitor of p38 MAP kinase. P38 MAP kinase is involved in response to stress and cytokines. If RP23-132J20.17 activity is modulated through the p38 MAPK pathway, this inhibitor would decrease its functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, thereby preventing the activation of the MAPK/ERK signaling pathway. If RP23-132J20.17 is activated by this pathway, U0126 would lead to a reduction in its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is part of the MAPK family. By inhibiting JNK, this compound could reduce the activity of RP23-132J20.17 if JNK signaling influences its activity. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $153.00 $356.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor. Aurora kinases play roles in cell division. If RP23-132J20.17 is involved in cell cycle regulation and is affected by Aurora kinase activity, this compound would reduce its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a potent inhibitor of several tyrosine kinases including Bcr-Abl and Src family kinases. If RP23-132J20.17 is activated by Src family kinase signaling, Dasatinib would inhibit its activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib is a proteasome inhibitor. If RP23-132J20.17 is regulated via proteasomal degradation, inhibition of the proteasome by Bortezomib would lead to decreased function of RP23-132J20.17. | ||||||